Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2018 Apr 25

PMID 29685789

Citations 10

Authors

Sukanya Panja

Sheida Hayati

Nusrat J Epsi

James Scott Parrott

Antonina Mitrofanova

Affiliations

Soon will be listed here.

Abstract

Therapeutic resistance is a central problem in clinical oncology. We have developed a systematic genome-wide computational methodology to allow prioritization of patients with favorable and poor therapeutic response. Our method, which integrates DNA methylation and mRNA expression data, uncovered a panel of 5 differentially methylated sites, which explain expression changes in their site-harboring genes, and demonstrated their ability to predict primary resistance to androgen-deprivation therapy (ADT) in the TCGA prostate cancer patient cohort (hazard ratio = 4.37). Furthermore, this panel was able to accurately predict response to ADT across independent prostate cancer cohorts and demonstrated that it was not affected by Gleason, age, or therapy subtypes. We propose that this panel could be utilized to prioritize patients who would benefit from ADT and patients at risk of resistance that should be offered an alternative regimen. Such approach holds a long-term objective to build an adaptable accurate platform for precision therapeutics.

Citing Articles

Evaluation of ALKBH2 and ALKBH3 gene regulation in patients with adult T-cell leukemia/lymphoma.

Wada Y, Naito T, Fukushima T, Saito M Virol J. 2024; 21(1):316.

PMID: 39633427 PMC: 11619432. DOI: 10.1186/s12985-024-02590-w.

Building Minimized Epigenetic Clock by iPlex MassARRAY Platform.

Davydova E, Perenkov A, Vedunova M Genes (Basel). 2024; 15(4).

PMID: 38674360 PMC: 11049545. DOI: 10.3390/genes15040425.

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC.

Panja S, Truica M, Yu C, Saggurthi V, Craige M, Whitehead K Nat Commun. 2024; 15(1):352.

PMID: 38191557 PMC: 10774320. DOI: 10.1038/s41467-024-44686-5.

A ferroptosis-related prognostic model with excellent clinical performance based on the exploration of the mechanism of oral squamous cell carcinoma progression.

Fan X, Zhong Y, Yuan F, Zhang L, Cai Y, Liao L Sci Rep. 2023; 13(1):1461.

PMID: 36702843 PMC: 9880000. DOI: 10.1038/s41598-023-27676-3.

Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer.

Panja S, Rahem S, Chu C, Mitrofanova A Curr Genomics. 2022; 22(4):244-266.

PMID: 35273457 PMC: 8822229. DOI: 10.2174/1389202921999201224110101.

References

Epstein J, Amin M, Beltran H, Lotan T, Mosquera J, Reuter V . Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38(6):756-67. PMC: 4112087. DOI: 10.1097/PAS.0000000000000208. View

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4):232-40. DOI: 10.3322/canjclin.22.4.232. View

Eyre R, Harvey I, Stemke-Hale K, Lennard T, Tyson-Capper A, Meeson A . Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population. Tumour Biol. 2014; 35(10):9879-92. DOI: 10.1007/s13277-014-2277-2. View

Gifford G, Paul J, Vasey P, Kaye S, Brown R . The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004; 10(13):4420-6. DOI: 10.1158/1078-0432.CCR-03-0732. View

Van Dam H, Castellazzi M . Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis. Oncogene. 2001; 20(19):2453-64. DOI: 10.1038/sj.onc.1204239. View

Tulchinsky E . Fos family members: regulation, structure and role in oncogenic transformation. Histol Histopathol. 2000; 15(3):921-8. DOI: 10.14670/HH-15.921. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Litovkin K, Van Eynde A, Joniau S, Lerut E, Laenen A, Gevaert T . DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS One. 2015; 10(6):e0130651. PMC: 4472347. DOI: 10.1371/journal.pone.0130651. View

Johnson A, Akman K, Calimport S, Wuttke D, Stolzing A, de Magalhaes J . The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res. 2012; 15(5):483-94. PMC: 3482848. DOI: 10.1089/rej.2012.1324. View

10.

Jones P, Baylin S . The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3(6):415-28. DOI: 10.1038/nrg816. View

11.

Miller H, Frampton A, Malczewska A, Ottaviani S, Stronach E, Flora R . MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocr Relat Cancer. 2016; 23(9):711-26. DOI: 10.1530/ERC-16-0044. View

12.

Zhang X, Asiedu C, Supakar P, Khan R, Ehrlich K, Ehrlich M . Binding sites in mammalian genes and viral gene regulatory regions recognized by methylated DNA-binding protein. Nucleic Acids Res. 1990; 18(21):6253-60. PMC: 332489. DOI: 10.1093/nar/18.21.6253. View

13.

Cai C, Wang H, He H, Chen S, He L, Ma F . ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013; 123(3):1109-22. PMC: 3582143. DOI: 10.1172/JCI66666. View

14.

Guinney J, Wang T, Laajala T, Kanigel Winner K, Bare J, Chaibub Neto E . Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2016; 18(1):132-142. PMC: 5217180. DOI: 10.1016/S1470-2045(16)30560-5. View

15.

Morris T, Beck S . Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. Methods. 2014; 72:3-8. PMC: 4304832. DOI: 10.1016/j.ymeth.2014.08.011. View

16.

Kohli M, Wang L, Xie F, Sicotte H, Yin P, Dehm S . Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy. PLoS One. 2015; 10(12):e0145176. PMC: 4687867. DOI: 10.1371/journal.pone.0145176. View

17.

Ehrlich M . DNA methylation in cancer: too much, but also too little. Oncogene. 2002; 21(35):5400-13. DOI: 10.1038/sj.onc.1205651. View

18.

Dhingra P, Martinez-Fundichely A, Berger A, Huang F, Forbes A, Liu E . Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome Biol. 2017; 18(1):141. PMC: 5530464. DOI: 10.1186/s13059-017-1266-3. View

19.

Geybels M, Wright J, Bibikova M, Klotzle B, Fan J, Zhao S . Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics. 2016; 8:97. PMC: 5024414. DOI: 10.1186/s13148-016-0260-z. View

20.

Goel M, Khanna P, Kishore J . Understanding survival analysis: Kaplan-Meier estimate. Int J Ayurveda Res. 2011; 1(4):274-8. PMC: 3059453. DOI: 10.4103/0974-7788.76794. View